Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis

Company Overview

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing bacteriophage-based therapeutics to treat bacterial infections, including infections caused by antibiotic-resistant pathogens. Bacteriophages, or “phages,” are viruses that selectively target and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics.

The company’s pipeline includes investigational phage therapies for serious respiratory and systemic infections. Its lead programs have targeted infections caused by Pseudomonas aeruginosa, including pulmonary infections associated with cystic fibrosis and other chronic lung conditions, as well as infections caused by Staphylococcus aureus. Armata is evaluating these candidates in clinical studies and continues to research phage compositions and manufacturing approaches designed to improve their therapeutic potential.

Armata is headquartered in Marina del Rey, California, and conducts its development activities primarily in the United States. The company originated from C3J Therapeutics and adopted the Armata Pharmaceuticals name following its acquisition of C3J’s phage-therapy business. Todd R. Patrick serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $3.72 to $4.07
• 50-Day Range: $3.31 to $5.84
• 52-Week Range: $3.09 to $16.34
• Volume: 103,614 shs
• Average Volume: 385,641 shs
• Market Capitalization: $141.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Moderate Buy

Armata Pharmaceuticals Stock Analysis - MarketRank™

Armata Pharmaceuticals scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Armata Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Armata Pharmaceuticals has a consensus price target of $15.00, representing about 293.7% upside from its current price of $3.81.

Amount of Analyst Coverage

Armata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Armata Pharmaceuticals are expected to decrease in the coming year, from $0.50 to ($2.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Armata Pharmaceuticals is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Armata Pharmaceuticals is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.72% of the float of Armata Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Armata Pharmaceuticals has a short interest ratio ("days to cover") of 1.65, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Armata Pharmaceuticals has recently increased by 8.82%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Armata Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Armata Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Armata Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ARMP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

84.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

3.57% of the stock of Armata Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/08/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:ARMP
• CIK: 921114
• Web: www.armatapharma.com
• Phone: (310) 655-2928
• Fax: 310-665-2963
• Employees: 61
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Armata Pharmaceuticals: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +293.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 7.62
• P/E Growth: N/A
• Net Income: -$173.80 million
• Net Margins: -3,467.04%
• Pretax Margin: -3,467.04%
• Return on Equity: -12.24%
• Return on Assets: 32.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.11
• Quick Ratio: 0.11

Sales & Book Value

• Annual Sales: $4.90 million
• Price / Sales: 28.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.00) per share
• Price / Book: -0.64

Miscellaneous

• Outstanding Shares: 37,180,000
• Free Float: 5,763,000
• Market Cap: $141.66 million
• Optionable: Not Optionable
• Beta: 1.40